MétaCan
Menu
← Back to cohort

Efficacy and quality of life (QoL) of cabazitaxel/prednisone (Cbz) in Canadian metastatic castration resistant prostate cancer (mCRPC) patients (pts) with or without prior abiraterone acetate (Abi).

2014· article· en· W2595209185 on OpenAlexaffabout
Fred Saad, Eric Winquist, Stacey Hubay, Scott R. Berry, Hazem Assi, Éric Lévesque, Nathalie Aucoin, Piotr Czaykowski, Jean‐Baptiste Lattouf, Karine Alloul, John A. Stewart, Srikala S. Sridhar

Bibliographic record

VenueJournal of Clinical Oncology · 2014
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsPrincess Margaret Cancer CentreSanofi (Canada)CancerCare ManitobaHôtel-Dieu de QuébecSunnybrook Health Science CentreUniversity Health NetworkMoncton HospitalUniversity of TorontoLondon Health Sciences CentreGrand River HospitalUniversité de Montréal
Fundersnot available
KeywordsMedicineDocetaxelCabazitaxelProstate cancerInternal medicineDiscontinuationAdverse effectNeutropeniaFebrile neutropeniaEnzalutamideOncologySurgeryCancerChemotherapyAndrogen deprivation therapy

Abstract

fetched live from OpenAlex

5062^ Background: In the TROPIC study, Cbz was shown to improve overall survival in mCRPC pts post-docetaxel, however none of these pts had prior exposure to Abi. To better understand the impact of prior Abi treatment on Cbz efficacy and QoL, we evaluated Canadian pts enrolled in the International Phase IIIb/IV single arm Cbz study. Methods: In total 61 pts were enrolled from 9 centers (May 2011 to February 2012). Cbz efficacy (PSA Response Rate (RR, decline ≥50%)) and impact on QoL were analyzed as a function of prior Abi use. Results: Baseline and disease characteristics were similar between NoPriorAbi (n=35, 57%) and PriorAbi (n=26, 43%) groups, except for age and time between last docetaxel dose and progression (Table). Pts received a median of 9 cycles of prior docetaxel. 92% of pts were ECOG 0/1, with 88% having bone metastases and 25% visceral metastases. 31% of pts received prophylactic G-CSF. Median number of Cbz cycles received was similar between groups (NoPriorAbi= 6, PriorAbi= 7) as were PSA RR (NoPriorAbi= 42.4%, PriorAbi= 47.6%, p=0.78). QoL and pain were improved in Cbz pts with no significant difference observed based on prior Abi use (Table). Overall, treatment discontinuation was mainly due to progression (45.9%) and adverse events (32.8%). Most frequent grade 3/4 toxicities were anemia and fatigue (9.8%), with diarrhea, neutropenia and febrile neutropenia each observed in 8.2% of pts. Conclusions: Cbz efficacy and impact on QoL were not affected by prior Abi use. In routine clinical practice, toxicity rates observed were similar to the TROPIC study. Clinical trial information: NCT01254279. Variable Unit Total No Prior Abi Prior Abi P Median age Yrs 65 64 69 0.02 Time between last docetaxel dose and progression <0 mos 11.7 17.1 4.0 0.05 0-3 23.3 28.6 16.0 3-6 18.3 14.3 24.0 ≥6 46.7 40.0 56.0 Pts with ≥10 cycles of Cbz % 26.7 28.6 24.0 0.70 FACT-P ≥16 points ǂ % 14.8 12.1 19.1 0.70 FACT-P ≥6 points ǂ % 44.4 39.4 52.4 0.41 PCS subscale ≥2 points ǂ % 53.7 51.52 57.14 0.78 PCS pain subscale ≥2 points ǂ % 27.8 24.24 33.33 0.54 Pain response Rate * ǂ % 20.7 15.00 33.33 0.34 * as defined in TROPIC (de Bono 2010). ǂ Minimal clinically important difference observed on 2 consecutive cycles.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.901
Threshold uncertainty score0.197

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.166
GPT teacher head0.486
Teacher spread0.320 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations5
Published2014
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical Oncology→Same topicProstate Cancer Treatment and Research→French-language works237,207→